Crossmark

Effect of follicle-stimulating hormone dose on the risk of being classified as suboptimal responders according to the POSEIDON criteria

Published Online: 2024-10-18

Published Print: 2024-12

Authors

Hochberg, Alyssa https://orcid.org/0000-0001-7387-409X
Dahan, Michael H.

Yarali, Hakan

Vuong, Lan N.

Esteves, Sandro C.
License Information

Text and Data Mining valid from 2024-10-18

Version of Record valid from 2024-10-18
More Information

Article History

Received: 27 March 2024

Accepted: 10 October 2024

First Online: 18 October 2024

Declarations

:

: This study was performed in line with the principles of the Declaration of Helsinki. The study received ethical approval from the institutions’ ethics committees: Instituto Investiga, Brazil (CAAE 26429219.0.0000.5599); Hacettepe University, Turkey (KA-180070); and My Duc Hospital, Vietnam (05/18/DD-BVMD).

: Informed consent was waived due to the retrospective design of the study.

: MHD received unrestricted research grants from Merck Serono and Ferring. HY declares receipt of payment for lectures from Merck and Ferring. LNV receives speaker fees and conferences from Merck, Merck Sharp and Dohme (MSD), and Ferring and research grants from MSD and Ferring. SCE declares receipt of unrestricted research grants from Merck and lecture fees from Merck and MedEA. AH has no conflict of interest to declare.

Document is current